和譽-B(02256.HK)附屬在EORTC-NCI-AACR會議發佈PRMT5*MTA及口服KRASG12D項目的臨牀前研究成果
格隆匯10月23日丨和譽-B(02256.HK)公吿,公司附屬公司上海和譽生物醫藥科技有限公司("和譽醫藥")宣佈,和譽醫藥兩項臨牀前研究結果在10月於西班牙巴塞羅那舉行的第36屆國際分子靶標與癌症治療大會(EORTC-NCI-AACR會議,"ENA大會")上發佈。這兩項研究成果分別展示了和譽醫藥在研管線中潛在同類最優的PRMT5*MTA抑制劑ABSK131和口服KRASG12D小分子抑制劑ABSK141的最新臨牀前研究進展。作為全球最高質量的聚焦分子靶向與腫瘤治療的研究會議之一,ENA大會聚焦了腫瘤治療領域的創新藥物和創新療法的最新進展。
此為公司刊發的自願公吿。集團無法保證ABSK131及ABSK141最終將成功獲批上市。公司股東及潛在投資者於買賣公司股份時務請審慎行事。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.